Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1608 • ACR Convergence 2022
Vascular Effect of Treat to Target in Early Rheumatoid Arthritis Patients – A 5-year Prospective Study
Huan Meng¹, Isaac Cheng², Byran P Yan¹, Alex PW Lee¹, Ho So¹ and Lai-shan Tam², ¹The Faculty of Medicine, CUHK, Hong Kong, Hong Kong, ²The Chinese University of Hong Kong, Hong Kong, China
Background/Purpose: Rheumatoid arthritis (RA) is associated with accelerated atherosclerosis driven by chronic inflammation. We have previously reported that achieving sustained disease activity score 28 (DAS28)…
Abstract Number: 1733 • ACR Convergence 2022
Granzyme K Elicits a New Pathway for Complement Activation in RA Synovium
Anna Jonsson¹, Carlos Donado², Emma Gomez-Rivas¹ and Michael Brenner³, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: T cells are major drivers of rheumatoid arthritis (RA) pathogenesis. Most research has focused on CD4 T cells, but we have found that CD8+…
Abstract Number: 1768 • ACR Convergence 2022
Sex-Related Differences in Healthcare Utilization in Patients with Inflammatory Arthritis: A Population-based Study
Sanjana Tarannum¹, Jessica Widdifield¹, C. Fangyun Wang², Sindhu R. Johnson³, Paula Rochon¹ and Lihi Eder⁴, ¹University of Toronto, Toronto, ON, Canada, ²Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, ³Division of Rheumatology, Department of Medicine, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western and Mount Sinai Hospitals; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ⁴Women’s College Research Institute, Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: Delayed diagnosis of inflammatory arthritis (IA), including rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA), is associated with joint damage and disability.…
Abstract Number: 1957 • ACR Convergence 2022
Detangling Heterogeneity in Contemporary Undifferentiated Arthritis – a Large Cohort Study Using Latent Class Analysis
Nikolet den Hollander¹, Marloes Verstappen², Bastiaan van Dijk³, Annette van der Helm-van Mil⁴ and Hanna van Steenbergen³, ¹Leids Universitair Medisch Centrum, Leiden, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands, ³Leiden University Medical Centre (LUMC), Leiden, Netherlands, ⁴Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands
Background/Purpose: Undifferentiated arthritis (UA) is considered to be heterogenous and consists of subgroups, this notion is affirmed by differences in disease course, varying from spontaneous…
Abstract Number: 1974 • ACR Convergence 2022
Which ACR Response Definition Should Be Used for Disease Activity Claims in Approval Studies of Rheumatoid Arthritis? A Systematic Evaluation
Andreas Kerschbaumer¹, Victoria Konzett², Josef Smolen¹ and Daniel Aletaha³, ¹Medical University of Vienna, Vienna, Austria, ²Division of Rheumatology / Department of Medicine III / Medical University of Vienna, Vienna, Austria, ³Medical University Vienna, Wien, Austria
Background/Purpose: The American College of Rheumatology (ACR) response definition was developed in 1995 by Felson et al. as a composite outcome and has been the…
Abstract Number: 1992 • ACR Convergence 2022
Burden of Pain for Patients in the CorEvitasTM Rheumatoid Arthritis Registry
Joshua Baker¹, J Morel Symons², Jud C Janak³, Page Moore³, Elizabeth Kohl³, Bernice Gershenson³, Oksana Pugach³, Dave Webb⁴, Alan A Martin⁴, Didier Saurigny⁵ and Marguerite Bracher⁵, ¹University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, ²GlaxoSmithKline, Collegeville, PA, ³CorEvitas, LLC, Waltham, MA, ⁴GlaxoSmithKline, Brentford, United Kingdom, ⁵GlaxoSmithKline, Stevenage, United Kingdom
Background/Purpose: Pain is a hallmark symptom of RA that impacts patients' quality of life and informs therapeutic decisions that aim to reduce joint inflammation and…
Abstract Number: 2008 • ACR Convergence 2022
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Mechanistic Insight and Dosage Optimization Study of the Efficacy and Safety of Dazodalibep (VIB4920/HZN4920) in Patients with Rheumatoid Arthritis Having Inadequate Response to Conventional/Biological DMARDs
Alan Kivitz¹, Liangwei Wang², Ilias Alevizos², Michele Gunsior², Judith Falloon² and Gabor Illei³, ¹Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, ²Horizon Therapeutics, Gaithersburg, MD, ³Horizon Therapeutics, Rockville, MD
Background/Purpose: Dazodalibep (DAZ), a non-antibody biologic antagonist of CD40L, led to higher/durable response rates vs. placebo (PBO) in a double-blind, Phase 1b trial of patients…
Abstract Number: 2199 • ACR Convergence 2022
Primary Non-adherence to Biologics and Immunomodulatory Therapies for Rheumatoid Arthritis, Psoriatic Arthritis, and Spondyloarthritis Using Linked EHR and Pharmacy Claims Data
Jeffrey Curtis¹, Yujie Su², Cassie Clinton², Patrick Stewart³, Bryant England⁴, Tim Buekelman⁵ and Fenglong Xie², ¹Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Bendcare, Boca Raton, FL, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵FASTER, Hoover, AL
Background/Purpose: Many patients with autoimmune and inflammatory conditions discontinue biologics and other immunomodulatory medications prematurely, but many fail to even start (primary non-adherence). We examined…
Abstract Number: 2253 • ACR Convergence 2022
Sputum Cytokines Are Elevated in Rheumatoid Arthritis-Associated Interstitial Lung Disease
Timothy Wilson¹, Kevin D Deane², Jonathan Dekermanjian², Joyce Lee², Marie Feser³, Stephen Humphries⁴, Joshua Solomon⁴ and Kristen Demoruelle³, ¹University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ²University of Colorado Denver Anschutz Medical Campus, Denver, CO, ³University of Colorado Anschutz Medical Campus, Aurora, CO, ⁴National Jewish Health, Denver, CO
Background/Purpose: Interstitial lung disease (ILD) is a well-recognized comorbidity in rheumatoid arthritis (RA) that contributes significantly to morbidity and mortality. ILD is diagnosed in up…
Abstract Number: 0067 • ACR Convergence 2022
Cost Per Responder in RA Patients Failing First Line Treatment
Manuel Cardozo, Pharmalab PHL, Huixquilucan, Mexico
Background/Purpose: The Colombian healthcare system is under economic pressure like many other systems in the world. In that sense, treatment choice involves cost in addition…
Abstract Number: 0137 • ACR Convergence 2022
Polyarticular Arthritis and Osteolysis Caused by Mutations in the ASAH1 Gene: Farber Disease Clinical Presentations in the First-ever Natural History Study
Alexander Solyom¹, Kathleen Crosby², Nils Confer² and Jaime Lopez Valdez³, ¹Aceragen, Basel, Switzerland, ²Aceragen, Durham, NC, ³Centenario Hospital Miguel Hidalgo, Aguascalientes, Mexico
Background/Purpose: Farber disease is frequently misdiagnosed as polyarticular juvenile idiopathic arthritis or seronegative rheumatoid arthritis which leads to a delay in diagnosis for many patients.…
Abstract Number: 0245 • ACR Convergence 2022
Influence of Forced Vital Capacity Impairment on Treatment Selection and Outcomes in RA-ILD Patients Initiating a Biologic or Targeted-Synthetic DMARD
Bryant England¹, Michael George², Yangyuna Yang¹, Punyasha Roul³, Jorge Rojas⁴, Brian Sauer⁵, Grant Cannon⁶, Joshua Baker⁷, Jeffrey Curtis⁸ and Ted Mikuls⁹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pennsylvania, Philadelphia, PA, ³UNMC, Omaha, NE, ⁴George E. Wahlen Department of Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT, ⁵Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁶Salt Lake City VA, Salt Lake city, ⁷University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, ⁸Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁹Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Patients with RA-associated interstitial lung disease (RA-ILD) suffer from substantial morbidity and premature mortality. The optimal use of biologic/tsDMARDs in this population is poorly…
Abstract Number: 0261 • ACR Convergence 2022
Machine Learning and Computational Pathology Can Reveal Synovial Pathotypes in Mice and Humans
Richard Bell¹, Matthew Brendel², Justin Xiang³, AMP RA/SLE Consortium¹, Edward DiCarlo¹, Jennifer Anolik⁴, Laura Donlin¹, Dana Orange⁵, Edward Schwarz⁴, Lionel Ivashkiv¹ and Fei Wang², ¹Hospital for Special Surgery, New York, NY, ²Weil Cornell Medical College, New York, NY, ³Horace Grant High School, New York, NY, ⁴University of Rochester Medical Center, Rochester, NY, ⁵The Rockefeller University, New York, NY
Background/Purpose: Synovial pathotyping is a critical step in understanding the etiology of inflammatory arthritis as different pathotypes have differential response to therapy. Determining these pathotypes…
Abstract Number: 0278 • ACR Convergence 2022
The Use of Exposure-Adjusted Event Rates versus Exposure-Adjusted Incidence Rates in Adverse Event Reporting: Insights from Filgotinib Integrated Safety Data in RA
Patrick Durez¹, Eugen Feist², Ricardo Blanco³, Vijay Rajendran⁴, Nadia Verbruggen⁵, Katrien Van Beneden⁵ and James Galloway⁶, ¹Institute de Recherche Expérimentale et Clinique (IREC), Cliniques Universitaires Saint-Luc - Université Catholique de Louvain (UCL), Brussels, Belgium, ²Helios Clinic Vogelsang-Gommern, cooperation partner of the Otto von Guericke University Magdeburg, Magdeburg, Germany, ³Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴Galapagos NV, Gent, Belgium, ⁵Galapagos NV, Mechelen, Belgium, ⁶King's College London, London, United Kingdom
Background/Purpose: Reporting of treatment-emergent adverse events (TEAEs) in RA clinical trials can be summarized as exposure-adjusted incidence rates (EAIRs) or exposure-adjusted event rates (EAERs). Censored…
Abstract Number: 0295 • ACR Convergence 2022
Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic DMARDs: Results Through 5 Years from the SELECT-NEXT Study
Gerd Burmester¹, Filip Van den bosch², John Tesser³, Anna K Shmagel⁴, Yuanyuan Duan⁴, Nasser Khan⁵, Heidi Camp⁶ and Alan Kivitz⁷, ¹Charité University Medicine Berlin, Berlin, Germany, ²Department of Internal Medicine and Paediatrics, Ghent University and VIB Centre for Inflammation Research, Ghent, Belgium, ³Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ⁴AbbVie, Inc., North Chicago, IL, ⁵AbbVie, Inc., Abbott Park, IL, ⁶Abbvie, Winnetka, IL, ⁷Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA
Background/Purpose: In the phase 3 SELECT-NEXT study, upadacitinib (UPA) demonstrated efficacy at wk 12 and sustained efficacy up to wk 60 in patients with rheumatoid…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].